Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
NASH - Nonalcoholic Steatohepatitis
Open-data reference.
28 US clinical trials · 7 currently recruiting
Active & Recent Trials
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Akero Therapeutics
NCT06528314
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Inventiva Pharma
NCT04849728
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Perspectum
NCT04054310
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
Mayo Clinic
NCT04232566
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
Massachusetts General Hospital
NCT04833140
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
University of Minnesota
NCT03587831
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
Milton S. Hershey Medical Center
NCT06195943
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals
NCT03900429
LITMUS Imaging Study
University of Oxford
NCT05479721
Nonalcoholic Fatty Liver Disease in HIV Database
Johns Hopkins University
NCT05023044
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
Hanmi Pharmaceutical Company Limited
NCT04505436
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
Akero Therapeutics
NCT05039450
Statins for the Treatment of NASH
Mayo Clinic
NCT04679376
Tocotrienol Against the Progression of End Stage Liver Disease
Chandan Sen
NCT02581085
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Indiana University
NCT04383951
Novel MRE Technique to Assess a Risk Factor for Liver Cancer
Natalie Torok
NCT05165446
Hepatic Energy Fluxes in NASH and NAS Patients
University of Minnesota
NCT03997422
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
Cirius Therapeutics
NCT02784444
The Liver in the World Trade Center Health Program General Responder Cohort and Controls
Icahn School of Medicine at Mount Sinai
NCT03858920
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
NGM Biopharmaceuticals
NCT03912532
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis
Terns
NCT05415722
Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE
University of California, Los Angeles
NCT04591106
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
Madrigal Pharmaceuticals
NCT04643795
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
Rivus Pharmaceuticals
NCT04874233
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
Enanta Pharmaceuticals
NCT03783897
A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
Lipocine
NCT04685993
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
89bio
NCT05022693
Study of Gemcabene in Adults With FPLD
Elif Oral
NCT03508687
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 4 |
| Phase 2 | 9 |
| Phase 3 | 4 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the NASH - Nonalcoholic Steatohepatitis Trial Landscape
ClinicalTrials.gov lists 28 US studies indexed under NASH - Nonalcoholic Steatohepatitis, and 7 of those are currently open to recruitment — roughly 25% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for NASH - Nonalcoholic Steatohepatitis shows 4 late-stage studies (Phase 3 and Phase 4 combined) alongside 13 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for NASH - Nonalcoholic Steatohepatitis is led by Madrigal Pharmaceuticals with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 28 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for NASH - Nonalcoholic Steatohepatitis?
PlainTrial tracks 28 US clinical trials for NASH - Nonalcoholic Steatohepatitis, of which 7 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for NASH - Nonalcoholic Steatohepatitis?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.